![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
MT2024-06: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
![](https://studyfinder.umn.edu/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcW9FIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--51af2e182cce1eeaae2e1fb9966b2e6b1d91fde3/Image%2015.jpg)
Recruiting
To determine the safety and maximum tolerated dose (MTD) of VCAR33 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) after allogeneic hematopoietic cell transplantation (alloHCT)
Male or Female
Not specified
Inclusion Criteria:
• at least 18 years old
• relapsed following hematopoietic cell transplant (HCT)
• unable to do strenuous activity but able to walk and able to carry out work of a light or sedentary nature, such as light house work, office work
• Original alloHCT donor is available and willing to undergo apheresis
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
Exclusion Criteria:
• patients who have undergone more than one alloHCT
• ongoing active acute or chronic Graft vs Host Disease (GVHD) and are taking systemic immunosuppressive agents
• active CNS disease
• active or uncontrolled viral, bacterial, or fungal infection
• history of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy
• women who are pregnant or breast feeding
Biological: VCAR33
Cancer
Clinics and Surgery Center (CSC), Acute Leukemia, AML, Leukemia, Myeloid
Tatum Mistic - misti003@umn.edu
Joseph Maakaron
PHASE1
STUDY00021822
See this study on ClinicalTrials.gov